Latest filing published 24 Oct 2022 for ChemoCentryx, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Jennifer Lyn Herron in ChemoCentryx, Inc., where the filings describe the role as board member. We count 2 filings; the first trade dates from 28 June 2022 and the latest from 20 October 2022.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The newest entry dates from 24 October 2022: a transaction, in ChemoCentryx, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations